Texting to beat leukemia: study tests if phone reminders boost chemo adherence

NCT ID NCT06446661

Recruiting now Symptom relief Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests whether daily or weekly text message reminders help adolescents and young adults (ages 15-39) with acute lymphoblastic leukemia (ALL) take their oral chemotherapy medications (mercaptopurine and methotrexate) more consistently during maintenance therapy. Participants are split into three groups: high intensity (daily texts), low intensity (weekly texts), or standard care (no texts). The goal is to see if reminders improve adherence and to understand how patient factors like self-efficacy relate to taking medication on schedule.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: text message reminders
What this could lead to: If it works, this could show that simple text reminders improve how consistently patients take their oral chemotherapy, potentially leading to better treatment outcomes.
What could go wrong: This is a small, early-stage study with only 38 participants, so results may not apply to everyone. Text reminders may not significantly change adherence, and the study does not test long-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma T-lymphoblastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA T-CELL LYMPHOBLASTIC LYMPHOMA

Contacts and locations

Locations

University of Chicago Medicine Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.